20.1
Pulmoner Hipertansiyon: Sınıflandırma ve Patogenez
Pulmoner hipertansiyon (PH), ortalama pulmoner arteryal basıncın 25 mmHg veya daha fazla yükseldiği, vücut dinlenme halindeyken bile görülen ciddi bir…
Pulmoner hipertansiyon veya PH, 25 mm Hg veya daha yüksek istirahat ortalama pulmoner arter basıncını gösterir.
Pulmoner hipertansiyon, sol kalp hastalığı, akciğer hastalıkları veya hipoksi, kronik tromboembolik PH, multifaktöriyel mekanizmaları belirsiz PH ve pulmoner arteriyel hipertansiyon veya PAH olarak sınıflandırılabilir.
PAH, küçük arterlerde ve arteriyollerde vasküler değişiklikler ile karakterize, yüksek pulmoner arter basıncına ve vasküler dirence yol açan nadir, ölümcül bir durumdur.
PAH'daki anahtar mekanizmalar arasında pulmoner vasküler yeniden şekillenme, sürekli pulmoner vazokonstriksiyon, in situ tromboz ve pulmoner vasküler duvarın sertleştirilmesi yer alır.
Prostasiklin gibi azalmış vazoaktif mediatörler ve ET-1 gibi artmış vazokonstriktörler vazokonstriksiyona katkıda bulunur.
PH belirtileri nefes darlığı, yorgunluk, göğüs ağrısı ve senkopu kapsar.
PH için potansiyel terapötik seçenekler arasında cGMP sinyal stimülatörleri, nitrik oksit tedavileri, membran reseptör antagonistleri ve agonistleri ve iyon kanal blokerleri bulunur.
View the full transcript and gain access to JoVE Core videos
Q1: What is the diagnostic threshold for pulmonary hypertension?
Pulmonary hypertension is diagnosed when the resting mean pulmonary arterial pressure reaches 25 mm Hg or higher. This elevated pressure in the blood vessels transporting blood from the heart to the lungs can cause significant symptoms and lead to right heart failure. The condition affects overall quality of life and requires prompt medical evaluation.
Q2: How is pulmonary arterial hypertension different from other types of pulmonary hypertension?
Pulmonary arterial hypertension (PAH) is a rare, fatal form characterized by vascular changes in small arteries and arterioles, causing elevated pulmonary arterial pressure and vascular resistance. Unlike other PH types linked to left heart disease, lung disease, or blood clots, PAH involves distinct mechanisms including pulmonary vascular remodeling, sustained vasoconstriction, in situ thrombosis, and vascular wall stiffening.
Q3: What causes pulmonary vasoconstriction in pulmonary arterial hypertension?
Pulmonary vasoconstriction in PAH results from imbalanced vasoactive mediators. Decreased vasodilators like nitric oxide and prostacyclin reduce vessel widening, while increased vasoconstrictors like endothelin-1 (ET-1) promote narrowing and smooth muscle cell proliferation. This mediator imbalance drives sustained constriction and worsens vascular resistance.
Q4: What are the main symptoms of pulmonary hypertension?
Pulmonary hypertension symptoms include dyspnea (shortness of breath), fatigue, chest pain, and syncope (fainting). These symptoms typically worsen over time, progressively limiting patients' ability to perform routine activities. Early recognition of these signs is important for timely diagnosis and intervention.
Q5: What therapeutic mechanisms are used to treat pulmonary arterial hypertension?
Treatment for pulmonary arterial hypertension employs multiple mechanisms: cGMP signaling stimulators enhance vasodilation, nitric oxide therapies promote vessel widening, membrane receptor antagonists and agonists modulate vasoactive pathways, and ion channel blockers reduce vascular resistance. Treatment choice depends on PAH severity and patient health status.
Q6: How do the five classifications of pulmonary hypertension differ?
The five PH classifications are: PH due to left heart disease, PH from lung diseases or hypoxia, chronic thromboembolic PH (caused by blood clots), PH with unclear multifactorial mechanisms, and pulmonary arterial hypertension (PAH). Each classification relates to different underlying causes, treatment approaches, and prognoses, guiding clinical management decisions.
Q7: What structural changes occur in the pulmonary vasculature during pulmonary arterial hypertension?
PAH involves multiple vascular structural changes: pulmonary vascular remodeling alters vessel architecture, sustained vasoconstriction narrows blood vessels, in situ thrombosis causes clotting within vessels, and vascular wall stiffening reduces elasticity. These combined changes increase pulmonary arterial pressure and vascular resistance, progressively impairing lung blood flow.